A Shorter Symptom Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate to Severe COVID-19: A Real-World Analysis

被引：0
|
作者：
Bansal, S. [1 ]
Kalpakam, H. [1 ]
Bysani, S. [1 ]
Varsha, A. [1 ]
Mehta, R. M. [2 ]
机构：
[1] Apollo Specialty Hosp, Bangalore, Karnataka, India
[2] Apollo Hop, Dept Pulm Crit Care & Sleep Med, Bangalore, Karnataka, India
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3811
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality
    Miller, Gregory M.
    Ellis, J. Austin
    Sarangarajan, Rangaprasad
    Parikh, Amay
    Rodrigues, Leonardo O.
    Bruce, Can
    Chand, Nischal Mahaveer
    Smith, Steven R.
    Richardson, Kris
    Vazquez, Raymond
    Kiebish, Michael A.
    Haneesh, Chandran
    Granger, Elder
    Holtz, Judy
    Hinkle, Jacob
    Narain, Niven R.
    Goodpaster, Bret
    Smith, Jeremy C.
    Lupu, Daniel S.
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 359 - 375
  • [22] Use of remdesivir for COVID-19 in the real world: An analysis of US electronic medical records
    Asubonteng, Julius
    Haredasht, Sara
    Kuranz, Seth
    Chokkalingam, Anand
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 98 - 99
  • [23] Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score
    Sellers, Jacob
    Chang, Jongwha
    Jones, Jessica
    Hintze, Trager D.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 78
  • [24] IMPACT OF TIME INTERVAL FROM COVID-19 SYMPTOM ONSET TO HOSPITALIZATION: AN OUTCOME ANALYSIS
    Figueroa, Rene
    Molina, Paloma
    Villalobos, Ana
    Canto-Costal, Ana Cecilia
    Patron, Daniel
    Aguilar, Isaac
    Said, Mohamed Ziad-M.
    Mathew, Joan
    Mendez-Castro, Jesus
    Terrazas, Andrea
    Ghaou, Sammy
    Mongo, Joel
    Varon, Joseph
    CRITICAL CARE MEDICINE, 2024, 52
  • [25] Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland
    Tibble, Holly
    Mueller, Tanja
    Proud, Euan
    Hall, Elliott
    Kurdi, Amanj
    Robertson, Chris
    Bennie, Marion
    Woolford, Lana
    Laidlaw, Lynn
    Sterniczuk, Kamil
    Sheikh, Aziz
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2024, 34 (01)
  • [26] Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality
    Annie, Frank H.
    Sirbu, Cristian
    Frazier, Keely R.
    Broce, Mike
    Lucas, B. Daniel, Jr.
    PHARMACOTHERAPY, 2020, 40 (11): : 1072 - 1081
  • [27] Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study
    Wang, Wenjuan
    Snell, Luke B.
    Ferrari, Davide
    Goodman, Anna L.
    Price, Nicholas M.
    Wolfe, Charles D.
    Curcin, Vasa
    Edgeworth, Jonathan D.
    Wang, Yanzhong
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [28] Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study
    Wenjuan Wang
    Luke B Snell
    Davide Ferrari
    Anna L Goodman
    Nicholas M Price
    Charles D Wolfe
    Vasa Curcin
    Jonathan D Edgeworth
    Yanzhong Wang
    BMC Infectious Diseases, 22
  • [29] COVID-19 in children: Treatment patterns in the real-world hospital setting
    Rasouliyan, Lawrence
    Kumar, Vikas
    Long, Stacey
    Rao, Mitesh B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 24 - 25
  • [30] Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
    Kim, Taeyun
    Joo, Dong-Hyun
    Lee, Seung Woo
    Lee, Jaejun
    Lee, Sang Jin
    Kang, Jihun
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
12345